USPTO Examiner SKOKO III JOHN JOSEPH - Art Unit 1643

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
18630058STING SENSITIZING AGENTSApril 2024April 2025Abandon1210NoNo
18345892ANTI-ROR1 ANTIBODY CONJUGATES, COMPOSITIONS COMPRISING ANTI ROR1 ANTIBODY CONJUGATES, AND METHODS OF MAKING AND USING ANTI-ROR1 ANTIBODY CONJUGATESJune 2023July 2024Allow1311YesNo
18068936ANTIBODY DRUG CONJUGATES COMPRISING STING AGONISTSDecember 2022May 2024Allow1721YesNo
18068476ANTIBODY DRUG CONJUGATES COMPRISING STING AGONISTSDecember 2022May 2025Allow2910NoNo
17996313SITE-SPECIFIC ANTIBODY-DRUG CONJUGATES BY ADP-RIBOSYL CYCLASESOctober 2022March 2023Allow500NoNo
17938193DOSAGE REGIMEOctober 2022April 2024Abandon1820NoNo
17946782COMPOSITIONS AND METHODS RELATED TO ANTI-CD19 ANTIBODY DRUG CONJUGATESSeptember 2022June 2025Allow3320NoNo
17812735ANTICANCER COMBINATION THERAPYJuly 2022May 2025Abandon3410NoNo
17812498PROTEIN-POLYMER DRUG CONJUGATESJuly 2022March 2025Abandon3310NoNo
17812543PROTEIN-POLYMER-DRUG CONJUGATESJuly 2022November 2024Abandon2920NoNo
17582097PREPARATION METHOD OF NK CELLS AND USE THEREOF IN THE TREATMENT OF CANCERJanuary 2022August 2023Allow1810YesNo
17471723THERAPEUTIC BINDING MOLECULESSeptember 2021June 2023Allow2110YesNo
17437428APPLICATION OF COMBINATION OF QUINOLINE DERIVATIVE AND IMMUNOMODULATOR IN PREPARATION OF ANTITUMOR DRUGSSeptember 2021June 2025Abandon4510NoNo
17436146DRUG DELIVERY FOR COMBINATION OF EPIGENETIC MODULATION AND IMMUNE CHECKPOINT BLOCKADESeptember 2021April 2025Abandon4410NoNo
17464469Methods And Compositions For Modifying Transcription Factor Activity by Targeting The Human Mediator Complex Using Cell Penetrating Memetic Peptides And Methods of Treating Cancer Using The SameSeptember 2021October 2023Abandon2610NoNo
17460560ANTIBODIES BINDING PD-L1 AND USES THEREOFAugust 2021March 2023Allow1800YesNo
17369321Stabilized Formulations Containing Anti-CTLA-4 AntibodiesJuly 2021January 2025Abandon4230NoNo
17420691CONJUGATE COMPRISING LIGAND AND CEACAM5 ANTIBODY FAB FRAGMENTJuly 2021May 2025Abandon4701NoNo
17418145ANTI-OX40 MONOCLONAL ANTIBODY AND APPLICATION THEREOFJune 2021October 2024Allow4010YesNo
17416148FN14 ANTIBODIES AND USES THEREOFJune 2021October 2024Allow4010YesNo
17415529COMBINATION HBV THERAPYJune 2021May 2025Allow4711NoNo
17413107FLT3 AGONIST ANTIBODIES AND USES THEREOFJune 2021April 2025Allow4620YesYes
17303952GENETICALLY MODIFIED NATURAL KILLER CELLS FOR CD70-DIRECTED CANCER IMMUNOTHERAPYJune 2021March 2024Allow3311YesNo
17245476METHODS OF ADMINISTERING ANTI-TIM-3 ANTIBODIESApril 2021November 2024Abandon4310NoNo
17245474ANTI-TIM-3 ANTIBODIESApril 2021February 2025Abandon4610YesNo
17283988PHARMACEUTICAL COMPOSITION CONTAINING TAGGED SITE-ANTIHUMAN ANTIBODY FAB FRAGMENT COMPLEXApril 2021April 2024Allow3620NoNo
17277828TARGETING MOIETY-DRUG GRAFTED IMMUNE CELL COMPOSITIONS AND METHODS OF USEMarch 2021September 2024Allow4210YesNo
17169950REGIMENS, COMPOSITIONS AND METHODS WITH CAPSAICIN AND TNF-alpha INHIBITORFebruary 2021July 2024Allow4210YesNo
17248767ANTIBODIES, COMPOSITIONS, AND IMMUNOHISTOCHEMISTRY METHODS FOR DETECTING C4.4AFebruary 2021March 2023Allow2500NoNo
17155936USE OF ANTI-CD137 ANTIBODY DRUG CONJUGATE (ADC) IN ALLOGENEIC CELL THERAPYJanuary 2021May 2025Allow5130YesNo
17140299MODULATING RESPONSES TO CHECKPOINT INHIBITOR THERAPYJanuary 2021March 2024Abandon3811NoNo
17256508Anti-SIRP-Beta1 Antibodies and Methods of Use ThereofDecember 2020March 2024Allow3911YesNo
17255064IMMUNOCONJUGATES TARGETING ADAM9 AND METHODS OF USE THEREOFDecember 2020May 2024Abandon4111NoNo
17254795TREATMENT OF CANCER WITH CLEVER-1 INHIBITION IN COMBINATION WITH PD-1/PD-L1 INHIBITORDecember 2020May 2024Abandon4030NoNo
17125500Antibodies binding to HLA-A2/MAGE-A4December 2020January 2024Allow3711YesNo
17116543Combination Therapy With LIV1-ADC and PD-1 AntagonistDecember 2020June 2024Abandon4221NoNo
17111816THERAPEUTIC METHODS USING ANTIBODY DRUG CONJUGATES (ADCS)December 2020April 2025Abandon5321NoNo
15734922TLR7 PEPTIDE CONJUGATESDecember 2020September 2024Abandon4610NoNo
16953580METHODS FOR ASSESSING EFFICACY OF MALT1 INHIBITORS USING AN NF-KB TRANSLOCATION ASSAYNovember 2020May 2024Abandon4120NoNo
16953597NF-KB REGULATED GENE EXPRESSION ASSAY FOR ASSESSING EFFICACY OF MALT1 INHIBITORSNovember 2020April 2024Abandon4120NoNo
17054920TREATMENT OF CANCERNovember 2020September 2024Allow4620YesNo
17093370EPHA3 DIRECTED CAR-T CELLS FOR TREATMENT OF TUMORSNovember 2020June 2024Allow4321YesNo
17053753METHODS OF TREATING CANCER WITH A COMBINATION OF AN ANTI-PD-1 ANTIBODY AND AN ANTI-TISSUE FACTOR ANTIBODY-DRUG CONJUGATENovember 2020November 2024Allow4830YesNo
17083556ANTI-CD47 BASED TREATMENT OF BLOOD CANCEROctober 2020October 2024Allow4850YesNo
17044952T-CELL INDUCING VACCINE COMPOSITION COMBINATION AND USES THEREOFOctober 2020February 2024Abandon4110NoNo
16966789COMBINATION OF CELLULAR IMMUNOTHERAPYOctober 2020August 2024Allow4910YesNo
17042013DRUG CONJUGATES OF cMET MONOCLONAL BINDING AGENTS, AND USES THEREOFSeptember 2020March 2024Allow4210NoNo
17030335CBL INHIBITORS AND COMPOSITIONS FOR USE IN ADOPTIVE CELL THERAPYSeptember 2020May 2024Allow4431YesNo
16982887CANCER VACCINE COMPOSITIONS AND METHODS OF USE THEREOFSeptember 2020January 2025Allow5220YesNo
16982095Novel peptide-based compounds for use in the prevention, treatment and/or detection of cancerSeptember 2020May 2024Allow4410YesNo
16981462ANTIGENIC PEPTIDES DERIVING FROM PCSK2 AND USES THEREOF FOR THE DIAGNOSIS AND TREATMENT OF TYPE 1 DIABETESSeptember 2020February 2025Abandon5320NoNo
16980318ANTI-HER2 BIPARATOPIC ANTIBODY-DRUG CONJUGATES AND METHODS OF USESeptember 2020May 2023Abandon3201NoNo
16979251Use of Anti-HER2 Antibody-Drug Conjugate in Cancer TreatmentSeptember 2020September 2024Allow4811NoNo
16976577A METHOD OF MODULATING CELL PROLIFERATIONAugust 2020August 2023Allow3620NoNo
16967509IMMUNOMODULATORY NANOFILAMENTSAugust 2020June 2024Allow4610YesNo
16963894CANNABINOIDS AND DERIVATIVES FOR PROMOTING IMMUNOGENICITY OF TUMOR AND INFECTED CELLSJuly 2020May 2023Abandon3310NoNo
16961346SUBCUTANEOUS ADMINISTRATION OF ANTI-CD38 ANTIBODIESJuly 2020March 2025Allow5640YesNo
16925802ANTHRACYCLINE-BASED ANTIBODY DRUG CONJUGATES HAVING HIGH IN VIVO TOLERABILITYJuly 2020June 2024Allow4830NoNo
16957075ROR1-SPECIFIC ANTIGEN BINDING MOLECULESJune 2020February 2025Allow5621YesNo
16868388COMPOSITIONS AND METHODS TO ENHANCE CUTANEOUS WOUND HEALINGMay 2020October 2023Allow4221NoNo
16760607HEAT-INACTIVATED VACCINIA VIRUS AS A VACCINE IMMUNE ADJUVANTApril 2020October 2024Abandon5341NoNo
16758980BIOACTIVE MOLECULE CONJUGATE, PREPARATION METHOD AND USE THEREOFApril 2020November 2023Allow4321YesNo
16650273METHOD FOR PRODUCING ANTIBODY-DRUG CONJUGATE INTERMEDIATE BY ADDITION OF ACID AND USE THEREOFMarch 2020September 2023Allow4221NoNo
16650337ANTI-CKAP4 MONOCLONAL ANTIBODYMarch 2020September 2023Allow4120NoNo
16637705BISPECIFIC ANTIGEN-BINDING MOLECULEFebruary 2020August 2024Abandon5531NoNo
16738115COMBINATION CANCER THERAPYJanuary 2020May 2025Abandon6051NoNo
16728045ANTIBODY-DRUG CONJUGATES AND RELATED COMPOUNDS, COMPOSITIONS AND METHODSDecember 2019August 2024Abandon5531YesNo
16625835A NOVEL TUMOR VACCINE AND USES THEREOFDecember 2019May 2023Allow4121YesNo
16493605SELECTIVE CELL DEATH-INDUCING ENZYME SYSTEMSeptember 2019September 2024Allow6011YesNo
16483332KRAS PEPTIDE VACCINE COMPOSITIONS AND METHOD OF USEAugust 2019May 2023Allow4511YesNo
16478297ANTI-CANCER TREATMENTS WITH AN ANTI-MUC1 ANTIBODY AND AN ERBB INHIBITORJuly 2019December 2023Abandon5350NoNo
16444691ANTI-PD-1 ANTIBODIES AND USES THEREOFJune 2019June 2025Allow6060YesYes
16408002COMPOSITIONS AND METHODS RELATED TO ANTI-CD19 ANTIBODY DRUG CONJUGATESMay 2019June 2022Allow3721YesNo
16334301ANTIBODY-POLYMER-DRUG CONJUGATESMarch 2019June 2023Allow5131NoNo
16329577CHIMERIC PROTEINS FOR TARGETING dsRNAFebruary 2019April 2023Allow4911YesNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner SKOKO III, JOHN JOSEPH.

Strategic Value of Filing an Appeal

Total Appeal Filings
2
Allowed After Appeal Filing
0
(0.0%)
Not Allowed After Appeal Filing
2
(100.0%)
Filing Benefit Percentile
0.5%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 0.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.

Strategic Recommendations

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner SKOKO III, JOHN JOSEPH - Prosecution Strategy Guide

Executive Summary

Examiner SKOKO III, JOHN JOSEPH works in Art Unit 1643 and has examined 74 patent applications in our dataset. With an allowance rate of 62.2%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 42 months.

Allowance Patterns

Examiner SKOKO III, JOHN JOSEPH's allowance rate of 62.2% places them in the 15% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by SKOKO III, JOHN JOSEPH receive 1.78 office actions before reaching final disposition. This places the examiner in the 54% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by SKOKO III, JOHN JOSEPH is 42 months. This places the examiner in the 4% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.

Interview Effectiveness

Conducting an examiner interview provides a +59.1% benefit to allowance rate for applications examined by SKOKO III, JOHN JOSEPH. This interview benefit is in the 97% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 32.7% of applications are subsequently allowed. This success rate is in the 62% percentile among all examiners. Strategic Insight: RCEs show above-average effectiveness with this examiner. Consider whether your amendments or new arguments are strong enough to warrant an RCE versus filing a continuation.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 44.4% of cases where such amendments are filed. This entry rate is in the 62% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 100.0% of appeals filed. This is in the 85% percentile among all examiners. Of these withdrawals, 100.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.

Petition Practice

When applicants file petitions regarding this examiner's actions, 75.0% are granted (fully or in part). This grant rate is in the 90% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 2% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 2% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.
  • Appeal filing as negotiation tool: This examiner frequently reconsiders rejections during the appeal process. Filing a Notice of Appeal may prompt favorable reconsideration during the mandatory appeal conference.
  • Plan for extended prosecution: Applications take longer than average with this examiner. Factor this into your continuation strategy and client communications.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.